HighRAD

132 Menachem Begin St. Azrieli Center, Round Tower Fl.22. P.O.B 67, Tel Aviv 6702101, Israel  All Israel companies →
Imaging AI Specialist Specialty-Focused AI
Nuclear Medicine Oncology Radiology
Oncology AI

Products

iCAS-LV
HighRAD
Oncology AI
HighRAD's iCAS-LV™ is an FDA-cleared AI imaging platform for quantitative volumetric changes analysis of liver lesions, designed to accelerate oncology reporting and track disease progression through automated detection, segmentation, and RECIST 1.1 documentation.

See all 1 product →

About HighRAD

HighRAD is an innovative healthcare AI company that provides an FDA-cleared oncology AI imaging platform. This platform is designed to offer fully automated, quantitative, and comparative analysis for the accurate evaluation of disease progression and treatment efficacy across a range of clinical applications.

The company’s cutting-edge technology aims to revolutionize oncology care by enhancing disease understanding through longitudinal, multi-organ quantitative analysis. This approach is intended to lead to improved treatment outcomes and patient care, while also boosting radiologist productivity and enabling quicker, more confident diagnoses. HighRAD’s system integrates seamlessly with all CT, MRI, and PET systems and is adaptable to various clinical protocols. Its technical foundation lies in proprietary Simultaneous Deep Learning technology (SimU-Net) and multi-channel anisotropic 3D U-Net classification, which allows for unparalleled lesion change detection and segmentation.

HighRAD’s platform is built around its novel Region of Difference (ROD) generic platform and methodology, enabling automatic, robust, and accurate lesion change analysis in longitudinal volumetric scans. This includes providing AI assistance for quantitative comparative measurement of all lesions, classifying them by type and size, and evaluating treatment or drug responses in clinical studies. The company’s comprehensive longitudinal quantitative change analysis is further supported by a novel annotation bootstrapping method, facilitating rapid development of deep learning classification with minimal annotated databases.

Focus Areas

oncology AI imaging quantitative volumetric analysis automatic lesion detection and segmentation longitudinal quantitative change analysis treatment efficacy evaluation disease progression tracking radiologist productivity personalized treatment planning pharmaceutical tool

Business Intelligence

Technologyproprietary Simultaneous Deep Learning technology (SimU-Net), multi-channel anisotropic 3D U-Net classification, Region of Difference™ (ROD™) generic platform

What Physicians Need to Know

Oncology AI Imaging Platform
HighRAD offers an FDA-cleared oncology AI imaging platform designed to track the entire patient journey, providing profound insights into disease progression through advanced quantitative, multi-organ analysis.
Longitudinal Quantitative Analysis
The company specializes in AI-powered longitudinal quantitative analysis, delivering fully automated, quantitative, and comparative analysis for accurate evaluation of disease progression and treatment efficacy across multiple organs.
Automatic Lesion Detection & Segmentation
HighRAD's technology provides AI-generated lesion detection for faster oncology reporting and accurate volumetric measurement of both known and unknown lesions.
Volumetric Measurements
The platform offers precise volumetric measurements of lesions and classifies them by type and size, enabling longitudinal comparison of findings through all available studies.
Personalized Treatment Planning Support
HighRAD leverages comprehensive and quantitative data analysis to track disease progression and optimize treatment plans, supporting personalized treatment planning.
Pharmaceutical Tool
The AI assistance aids in quantitative comparative measurement to evaluate treatment or drug responses and track clinical studies, serving as a valuable pharmaceutical tool.
Streamlining Imaging Workflow Processes
HighRAD's solutions are designed to streamline imaging workflow processes within healthcare facilities, leading to higher productivity and patient throughput.
Improving Clinical Outcomes
By enhancing disease progression understanding through longitudinal, multi-organ quantitative analysis, HighRAD aims to improve treatment outcomes and patient care.
Organ-Specific Lesion Analysis
HighRAD offers specialized modules for different organs: iCAS-LV for liver lesion analysis, iCAS-LG for pulmonary metastases analysis, and iCAS-BR for brain lesion analysis.
Physician Tip

HighRAD's platform empowers physicians with AI-generated lesion detection for up to 3x faster oncology reporting and accurate volumetric measurements. Its longitudinal comparison capabilities across all available studies, combined with automated RECIST 1.1 documentation, streamline reporting and provide greater clinical depth. The multi-organ view ensures comprehensive standardized reporting, aiding in a quicker, more confident diagnosis and enhanced understanding of disease progression for improved treatment outcomes.

HighRAD's system offers seamless connectivity, integrating with all CT, MRI, and PET systems and is adaptable to various clinical protocols. This ensures easy integration into existing healthcare imaging workflows.

Products by HighRAD

1 product in the directory

iCAS-LV
HighRAD
Oncology AI
HighRAD's iCAS-LV™ is an FDA-cleared AI imaging platform for quantitative volumetric changes analysis of liver lesions, designed to accelerate oncology reporting and track disease progression through automated detection, segmentation, and RECIST 1.1 documentation.

What the Web Says

HighRAD (also referred to as HighRadius) offers AI-driven solutions primarily for accounts receivable, aiming to automate financial outcomes and processes for CFOs. Users generally praise its automation capabilities, ease of use, and efficiency in streamlining AR processes, such as cash application, collections, and payment matching. However, a recurring concern across reviews is the poor customer support, characterized by slow response times and ineffective issue resolution.

Overall: Mixed

Strengths

  • Automation capabilities, enhancing efficiency and reducing manual tasks.
  • Ease of use, simplifying reconciliation processes.
  • Improved collections efficiency and cash flow.
  • User-friendly interface and easy to learn.
  • Good dashboards and reporting features for visibility into outstanding invoices.
  • Seamless integration with ERP systems.

Limitations

  • Poor customer support with frustrating response times and ineffective escalation processes.
  • Payment issues due to slow search capabilities and limitations in remittance format recognition.
  • Limited functionality for critical tracking tasks.
  • Missing features, particularly in connectivity, custom rules, and analytics.
  • Slow performance, affecting job speed and file upload efficiency.
  • Difficult to make changes once background rules are set up.

Based on reviews from: G2, Capterra

Last updated: 2026-10-18

Videos

News, demos, and interviews about HighRAD.

Loading videos...

Videos load interactively. If none appear, search YouTube for HighRAD →

View all on YouTube

Press & Coverage

20/20 HealthCare Partners
HighRad - 20/20 HealthCare Partners
HighRad is developing an innovative AI Imaging platform to transform oncology care by tracking the entire patient journey and providing insights into disease progression through advanced quantitative, multi-organ analysis.
2024-10
HighRAD
HighRAD | Revolutionizing Oncology Care
HighRAD's oncology AI imaging platform enhances disease understanding, improves treatment outcomes, and boosts radiologist productivity by streamlining imaging workflow processes.
unknown
Hadasit - Health Innovation Engine
HighRad - Hadasit - Health Innovation Engine
Hadasit, the technology transfer company of Hadassah Medical Organization, features HighRad as part of its portfolio of health innovations.
2024-03
HighRAD
About - HighRAD
HighRAD offers an FDA-cleared oncology AI imaging platform for automated, quantitative, and comparative analysis to evaluate disease progression and treatment efficacy.
unknown
HighRAD
Technology - HighRAD
HighRAD's technology utilizes proprietary Simultaneous Deep Learning (SimU-Net) and multi-channel anisotropic 3D U-Net classification for unparalleled lesion change detection and segmentation, offering seamless integration with existing imaging systems.
unknown
PR Newswire
Rad AI Announces Strategic Investments from Four Leading Health Systems to Advance Enterprise AI in Healthcare - PR Newswire
Rad AI, a company focused on enterprise AI in healthcare, announced an additional $8 million strategic investment from four leading health systems, bringing its total Series C funding to $68 million.
2025-05
PubMed
Artificial Intelligence in Health Care: A Rallying Cry for Critical Clinical Research and Ethical Thinking - PubMed
This article discusses the impact of AI in healthcare, particularly in diagnostic radiology and digital pathology, and the emerging research on AI tools in radiation oncology workflows.
2025-05
PubMed
Medical hyperspectral imaging: an updated review of technology advancements and biomedical applications - PubMed
This review highlights recent advancements in medical hyperspectral imaging (HSI) technology, including sensor improvements, data processing, and deep-learning/AI tools, with various applications in oncology and other medical fields.
2026-03

Frequently Asked Questions

HighRAD provides AI-powered solutions for automatic lesion detection and segmentation, longitudinal quantitative analysis, and volumetric measurements across various oncology indications. Our products, such as iCAS-LV (liver), iCAS-LG (pulmonary), and iCAS-BR (brain), are designed to integrate seamlessly with existing PACS and EHR systems through standard protocols like DICOM and HL7, aiming to streamline imaging workflow processes and enhance data accessibility for physicians.
HighRAD's AI tools offer precise quantitative analysis of lesions, including volumetric measurements and tracking changes over time, which are crucial for personalized treatment planning. By providing objective and consistent data, our solutions assist physicians in making more informed decisions, monitoring treatment response effectively, and ultimately striving to improve clinical outcomes for cancer patients.
HighRAD is committed to achieving and maintaining regulatory compliance for all its AI imaging products, including FDA clearance and CE Mark certification, as applicable to the markets we serve. We adhere to stringent data security and privacy protocols, including HIPAA and GDPR, by implementing robust encryption, access controls, and anonymization techniques to protect sensitive patient information.
HighRAD offers flexible pricing models tailored to the needs of different healthcare institutions, which can include subscription-based licensing or per-study fees. Our commitment extends beyond product delivery to comprehensive technical support, including dedicated account management, on-site or remote training for clinical staff, and ongoing maintenance to ensure optimal performance and user satisfaction.
HighRAD actively pursues strategic partnerships with pharmaceutical companies and leading research institutions to further validate our AI algorithms and expand their applications. These collaborations often involve using our tools as a pharmaceutical tool for clinical trials, biomarker discovery, and developing new endpoints, which in turn enhances the capabilities and clinical utility of our oncology AI solutions.
HighRAD's long-term vision is to be a leader in oncology AI imaging, continuously innovating to provide cutting-edge solutions that transform cancer care. We are a stable company with a clear roadmap for future product development, focusing on expanding our AI capabilities to new cancer types, integrating with emerging technologies, and further enhancing our longitudinal quantitative analysis and personalized treatment planning support.

Related Companies

SOPHiA GENETICS is a healthcare AI company that has developed a cloud-native, AI-driven SaaS platform called SOPHiA DDM™. This platform is designed to enable hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data. The company’s mission is to democratize data-driven medicine, providing actionable insights […]

NTL Healthcare is a South Korean AI-powered women’s health company specializing in cervical cancer screening and diagnostics. The company has a history dating back to 1996 when it first introduced an analog cervical cancer reading system, Cervicography, to Korea. Since then, NTL Healthcare has evolved its technology, developing the world’s first remote uterine cervical cancer […]

Lumonus is a healthcare technology company that specializes in AI-powered solutions for cancer care, particularly in radiation oncology. The company’s core offering is the Lumonus AI platform, a digital oncology system with AI-native clinical infrastructure designed to automate and orchestrate critical oncology workflows. This platform aims to enhance the quality and speed of care delivery […]

Deep Bio is a healthcare AI company that develops deep learning-based cancer diagnostic support software, aiming to advance patient outcomes by empowering clinicians with innovative technology. Their mission is to provide tools that enable medical professionals to make critical decisions, ultimately enhancing healthcare delivery and allowing clinicians to focus more on patient care. The company’s […]

AIRA Matrix is a healthcare AI company that develops cutting-edge artificial intelligence solutions for life sciences applications, with a strong emphasis on deep learning for medical image analysis. Their innovative products and services are designed to enhance diagnostic accuracy, improve workflow efficiency, and reduce turnaround times in pathology laboratories. The company provides diagnostic, prognostic, and […]

Surgical Reality is a healthcare AI company that specializes in advanced AI-powered 3D medical imaging and surgical planning software for thoracic surgery. Their core product, the Surgical Reality Viewer, converts standard CT scans into high-fidelity, patient-specific 3D models of the entire lung within minutes. This technology is designed to assist trained healthcare professionals with preoperative […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.